Redefining What’s Possible in Pharmaceutical R&D
With peptide innovation, in-vitro research, polymorphs and 505(b)(2) development, we turn complex chemistry into life-changing solutions.R&D has always been at the heart of Apothecon’s journey — from our origins as a research-first organization in 2007 to becoming a global player in specialized pharmaceuticals. Our two R&D centres house over 175 scientists, each working at the intersection of scientific precision and real-world patient need. We focus on non-infringing synthesis, complex generics, peptides, and next-gen formulations, driven by the belief that innovation should be both purposeful and accessible.
Our infrastructure includes a dedicated kilo lab, advanced analytical instruments like LCMS, UPLC, GCMS, 3D Microscopy, and process development tools such as Flow Reactors and Lyophilizers. From early-stage development to regulatory filing, every touchpoint is built for global compliance, innovation scalability, and measurable impact.
What We Specialize In
Our comprehensive clinical development program includes landmark studies that will define the future of treatment in key therapeutic areas.
Peptide Molecule Development
Niche APIs & Intermediates
Iron Complex MoleculesComplex Polymer MoleculesChiral Molecules & Polymorphism StudiesNon-Infringing Route Development for GenericsNovel Intermediates & Difficult-To-Make CompoundsPeptide Molecule DevelopmentNiche APIs & IntermediatesIron Complex MoleculesComplex Polymer MoleculesChiral Molecules & Polymorphism StudiesNon-Infringing Route Development for GenericsNovel Intermediates & Difficult-To-Make Compounds- Vertical Integration in oncology and non-oncology range of products
- Development of non-infringing API to support FTF (first to file) & Para IV filings
- Achieving cost efficiency through process optimization
- Generating IPR on process chemistry
- Our dedicated 2 R&D centres comprises around 175+ scientists are pushing the boundaries of science to develop innovative and effective cures for patients.
- Our advanced laboratories and modern technologies enable us to develop challenging molecules and push the boundaries of pharmaceutical development.
- Our team has expertise across developing niche molecules, complex iron molecules, peptide molecules, complex polymer molecules, chiral molecules, polymorphism and novel intermediate compounds. The core area of R&D work mainly focusing on development of generic molecules by non-infringing route of synthesis as well as innovative process.
